Clinical Trials on Transurethral Resection of Prostate in Japan

Total 4 results

Navitas Life Sciences GmbH
GE Healthcare; Bayer; Guerbet

Completed

Long-Term Retention of Gadolinium in Bone

Focus: Long-term Retention of Gadolinium-based Contrast Agent

Spain, Korea, Republic of, United States, Germany, Japan, Turkey
Andreas Benesic, MD
MetaHeps GmbH

Unknown

Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity

Adverse Reaction to Drug | Drug-induced Disorder of Liver

Hong Kong, Australia, Germany, Japan, Korea, Republic of
Pfizer

Recruiting

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i)

Breast Neoplasms | Prostate Cancer | Adenocarcinoma of Lung | Solid Tumors | Liposarcoma | CRC

China, United States, United Kingdom, Mexico, Czechia, Japan, Slovakia, Argentina
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

Urogenital Neoplasms | Prostatic Neoplasms | Neoplasm Metastasis | Enzyme Inhibitors | Antineoplastic Agents | Hormones | Physiological Effects of Drugs | Antineoplastic Agents, Hormonal | Androgens | Hormones, Hormone Substitutes, and Hormone Antagonists | Abiraterone Acetate | Steroid Synthesis Inhibitors | Cytochrome... and other conditions

China, Canada, France, United States, Australia, Czechia, Hungary, Spain, Germany, Japan, Taiwan, Netherlands, Mexico, Belgium, Korea, Republic of, Turkey, Argentina, Romania, United Kingdom, Italy, Israel, Brazil, Poland, Greece

Clinical Trials on Transurethral Resection of Prostate in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations